Biomarkers
The lane
- Status
- Enabler. Tools, methods and resources that the other lanes depend on.
- Verdict
- The seed test shows who has the disease, not how fast it progresses.
- Family
- Enabler
- Landmarks
- 17 in this lane, 5 more tagged with it. Advanced 9 · Open 7 · Superseded 1
The verdict and status come from the project's branches.yaml and use research wording.
Landmarks in this lane
| Fluorodopa PET | 1983 | Research tool | Confirmed and built on | – | – | 19 Oct 2026 | 3 |
| REM sleep behaviour disorder becomes Parkinson's | 1996–2019 | Discovery | Confirmed and built on | – | – | 19 Oct 2026 | 2 |
| DaTscan approved in the EU and US | 2000–2011 | Research tool | Confirmed and built on | – | – | 19 Oct 2026 | 3 |
| Smell loss predicts Parkinson's | 2004–2008 | Discovery | Confirmed and built on | – | – | 19 Oct 2026 | 3 |
| Neuromelanin MRI and nigrosome sign | 2006–2014 | Research tool | Still being studied | – | – | 19 Oct 2026 | 2 |
| Free-water MRI | 2009–2017 | Research tool | Still being studied | – | – | 19 Oct 2026 | 4 |
| Target-engagement markers for LRRK2 drugs | 2010–2023 | Research tool | Confirmed and built on | – | – | 19 Oct 2026 | 5 |
| CSF total synuclein | 2011–2013 | Discovery | Replaced by a better idea | – | – | 19 Oct 2026 | 3 |
| DAT scans qualified for trials | 2015–2018 | Research tool | Confirmed and built on | – | – | 20 Oct 2026 | 5 |
| RT-QuIC and PMCA: first synuclein amplification | 2016–2020 | Research tool | Confirmed and built on | – | – | 20 Oct 2026 | 3 |
| Neurofilament light | 2020 | Research tool | Still being studied | – | – | 20 Oct 2026 | 3 |
| Blood seed amplification | 2022–2023 | Research tool | Still being studied | – | – | 20 Oct 2026 | 4 |
| Seed amplification assay | 2023 | Research tool | Confirmed and built on | – | – | 20 Oct 2026 | 0 |
| Synuclein PET tracers | 2023–2026 | Research tool | Still being studied | – | – | 20 Oct 2026 | 3 |
| NSD-ISS and SynNeurGe definitions | 2024 | Research tool | Still being studied | – | – | 20 Oct 2026 | 3 |
| Skin-biopsy synuclein (Syn-One) | 2024 | Research tool | Still being studied | – | – | 20 Oct 2026 | 3 |
| FDA letter of support for the seed assay | 2024 | Research infrastructure | Confirmed and built on | – | – | 20 Oct 2026 | 2 |
Also tagged with this lane
| CALM-PD β-CIT and REAL-PET | 2002–2003 | Trial in people | Replaced by a newer approach | – | 268 | 19 Oct 2026 | 3 |
| PPMI launches | 2010 | Research infrastructure | Confirmed and built on | – | – | 19 Oct 2026 | 3 |
| Gut biopsies for synuclein | 2012–2016 | Discovery | Replaced by a better idea | – | – | 19 Oct 2026 | 3 |
| LRRK2 phosphorylates Rab proteins | 2016 | Discovery | Confirmed and built on | – | – | 20 Oct 2026 | 4 |
| Atomic structures of synuclein fibrils | 2018–2022 | Discovery | Confirmed and built on | – | – | 20 Oct 2026 | 4 |
Links with other lanes
Built on work from
- Infrastructure & funding: 8 links
- Synuclein misfolding & spread: 5 links
- LRRK2: 3 links
- Trial methods & regulation: 1 link
- Gut–brain origin: 1 link
- Foundations: 1 link
- Oxidative stress: 1 link
- Selective vulnerability: 1 link
Led to work in
- Trial methods & regulation: 4 links
- LRRK2: 1 link
- Infrastructure & funding: 1 link
- Synuclein lowering: 1 link
- Oxidative stress: 1 link